Published in Mol Immunol on May 02, 2006
Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines (2008) 1.13
Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics. Adv Drug Deliv Rev (2009) 1.07
Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins (Basel) (2012) 1.04
Purification, modeling, and analysis of botulinum neurotoxin subtype A5 (BoNT/A5) from Clostridium botulinum strain A661222. Appl Environ Microbiol (2011) 1.02
Identification of a unique ganglioside binding loop within botulinum neurotoxins C and D-SA . Biochemistry (2010) 1.01
Immunogenicity of botulinum toxins. J Neural Transm (Vienna) (2012) 0.99
Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library. MAbs (2014) 0.91
Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharmacol Rev (2017) 0.87
Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol (2011) 0.85
Subunit vaccine efficacy against Botulinum neurotoxin subtypes. Vaccine (2011) 0.81
Enhancing the protective immune response against botulism. Infect Immun (2013) 0.81
Unique ganglioside binding by botulinum neurotoxins C and D-SA. FEBS J (2011) 0.78
Epitope characterization of sero-specific monoclonal antibody to Clostridium botulinum neurotoxin type A. Hybridoma (Larchmt) (2011) 0.77
The C-terminal heavy-chain domain of botulinum neurotoxin a is not the only site that binds neurons, as the N-terminal heavy-chain domain also plays a very active role in toxin-cell binding and interactions. Infect Immun (2015) 0.77
Isolation of nanomolar scFvs of non-human primate origin, cross-neutralizing botulinum neurotoxins A1 and A2 by targeting their heavy chain. BMC Biotechnol (2015) 0.76
Epitope mapping of botulinum neurotoxins light chains. Toxicon (2012) 0.76
Antigenic sites on the HN domain of botulinum neurotoxin A stimulate protective antibody responses against active toxin. Sci Rep (2015) 0.75
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med (2009) 5.81
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet (2003) 3.39
Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet (2002) 2.90
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Movement disorders in cerebrovascular disease. Lancet Neurol (2013) 2.81
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Mov Disord (2006) 2.72
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol (2012) 2.50
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol (2008) 2.34
Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov Disord (2007) 2.34
The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain (2008) 2.34
Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet (2002) 2.27
Camptocormia: pathogenesis, classification, and response to therapy. Neurology (2005) 2.26
Mutations in the gene PRRT2 cause paroxysmal kinesigenic dyskinesia with infantile convulsions. Cell Rep (2011) 2.17
The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord (2011) 2.16
Are Parkinson disease patients protected from some but not all cancers? Neurology (2007) 2.12
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg (2006) 2.02
Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis (2006) 2.00
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet (2003) 1.98
Genetics of essential tremor. Brain (2007) 1.89
Update on blepharospasm: report from the BEBRF International Workshop. Neurology (2008) 1.87
Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem (2002) 1.86
Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx (2006) 1.82
Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord (2006) 1.82
Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord (2010) 1.76
Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist (2008) 1.74
Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci (2009) 1.73
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol (2011) 1.68
Premutation alleles associated with Parkinson disease and essential tremor. JAMA (2004) 1.65
Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun (2005) 1.64
Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci (2004) 1.62
Migraine headache in patients with Tourette syndrome. Arch Neurol (2003) 1.61
Minocycline in Huntington's disease: a pilot study. Mov Disord (2004) 1.59
Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat (2010) 1.57
Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol (2009) 1.56
Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord (2008) 1.56
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord (2005) 1.54
Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol (2005) 1.54
Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol (2003) 1.53
Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord (2010) 1.52
Secondary tics and tourettism. Rev Bras Psiquiatr (2005) 1.47
Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci (2011) 1.46
Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis (2008) 1.43
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics (2010) 1.37
Activation of TRPV1 mediates calcitonin gene-related peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum toxin with anti-nociceptive potential. J Neurosci (2009) 1.37
The safety and efficacy of thalamic deep brain stimulation in essential tremor: 10 years and beyond. J Neurol Neurosurg Psychiatry (2013) 1.36
Premonitory sensory phenomenon in Tourette's syndrome. Mov Disord (2003) 1.35
Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin (2004) 1.33
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord (2007) 1.32
Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord (2010) 1.31
Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease. Neurosignals (2011) 1.30
Plasma membrane localization signals in the light chain of botulinum neurotoxin. Proc Natl Acad Sci U S A (2004) 1.29
Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol (2006) 1.29
Genomewide scans in North American families reveal genetic linkage of essential tremor to a region on chromosome 6p23. Brain (2006) 1.29
Nurr1 in Parkinson's disease and related disorders. J Comp Neurol (2006) 1.27
Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon (2013) 1.27
Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol (2002) 1.26
Runner's dystonia. J Neurol Sci (2006) 1.24
Clinical heterogeneity of neurodegeneration with brain iron accumulation (Hallervorden-Spatz syndrome) and pantothenate kinase-associated neurodegeneration. Mov Disord (2004) 1.24
Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord (2006) 1.23
Iron dysregulation in movement disorders. Neurobiol Dis (2012) 1.22
A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. Proc Natl Acad Sci U S A (2006) 1.20
Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). Curr Neuropharmacol (2013) 1.20
An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov (N Y) (2013) 1.20
Movement disorders in systemic lupus erythematosus and the antiphospholipid syndrome. J Neural Transm (Vienna) (2013) 1.20
Essential tremor quantification during activities of daily living. Parkinsonism Relat Disord (2011) 1.18
Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord (2007) 1.18
Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology (2002) 1.18
Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord (2007) 1.17
Reliability of a new scale for essential tremor. Mov Disord (2012) 1.17
Secondary paroxysmal dyskinesias. Mov Disord (2002) 1.17
Correlation between Kinesia system assessments and clinical tremor scores in patients with essential tremor. Mov Disord (2010) 1.17
Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother (2006) 1.16
Movement disorders in autoimmune diseases. Mov Disord (2012) 1.16
Safety of MRI in patients with implanted deep brain stimulation devices. Neuroimage (2009) 1.16
The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry (2013) 1.15
Preclinical biomarkers of Parkinson disease. Arch Neurol (2011) 1.14
Head injury, α-synuclein Rep1, and Parkinson's disease. Ann Neurol (2012) 1.14
The genetics of Tourette syndrome. Nat Rev Neurol (2012) 1.13
Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol (2008) 1.12
Botulinum toxin type A normalizes alterations in urothelial ATP and NO release induced by chronic spinal cord injury. Neurochem Int (2007) 1.12
Randomized trial of IV valproate vs metoclopramide vs ketorolac for acute migraine. Neurology (2014) 1.11
Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci (2008) 1.10
Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. Exp Neurol (2005) 1.10
Complete DNA sequences of the botulinum neurotoxin complex of Clostridium botulinum type A-Hall (Allergan) strain. Gene (2003) 1.10
Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol (2002) 1.10
Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord (2010) 1.09